caa a22 4500 465789781 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171991 doi (NATIONALLICENCE)springer-10.1007/BF00171991 Phase II trial of intravenous melphalan for metastatic colorectal carcinoma [Elektronische Daten] A Southwest Oncology Group study [William Knight III, Phyllis Goodman, Sarah Taylor, John Macdonald, Charles Coltman Jr., John Constanzi, Laurence Baker] Summary: Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting dose of 40 mg/m2 was reduced to 30 mg/m2 after severe myelotoxicity was encountered in the first five patients. Toxicity was primarily myeloid and was moderate to severe in most patients with one treatment related death. There were two complete and one partial response among 43 patients. Melphalan at 30 mg/m2 has little activity among patients with metastatic colorectal carcinoma. Kluwer Academic Publishers, 1990 melphalan nationallicence colon cancer nationallicence Knight III William St. Louis University Medical Center, USA aut Goodman Phyllis Southwest Oncology Group Statistical Center, Seattle aut Taylor Sarah University of Kansas Medical Center, USA aut Macdonald John University of Kentucky Medical Center, USA aut Coltman Jr. Charles University of Texas Health Sciences Center at San Antonio, USA aut Constanzi John University of Texas, Galveston aut Baker Laurence Wayne State University Medical Center, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S87-S89 0167-6997 8<S87 1990 8 10637 https://doi.org/10.1007/BF00171991 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171991 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Knight III William St. Louis University Medical Center, USA aut NATIONALLICENCE 700 1- Goodman Phyllis Southwest Oncology Group Statistical Center, Seattle aut NATIONALLICENCE 700 1- Taylor Sarah University of Kansas Medical Center, USA aut NATIONALLICENCE 700 1- Macdonald John University of Kentucky Medical Center, USA aut NATIONALLICENCE 700 1- Coltman Jr Charles University of Texas Health Sciences Center at San Antonio, USA aut NATIONALLICENCE 700 1- Constanzi John University of Texas, Galveston aut NATIONALLICENCE 700 1- Baker Laurence Wayne State University Medical Center, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S87-S89 0167-6997 8<S87 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer